Occupational DiseasesSubstancesNCT07879261
Hazardous Substances Injuries
An observational study of Occupational Diseases, run by Sergio Gabriel Susmallian at 1 site in Israel.
Trial summary
This clinical study aims to evaluate the effectiveness and safety of [intervention or treatment] in patients with [clinical condition]. The study will investigate whether this intervention improves [primary clinical outcome] compared with [standard treatment or control group]. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Occupational Diseases
- What is being tested?
- Retrospective Administrative Data Assessment
- How many people
- 1,951 participants
- Where
- 1 siteIsrael
- Study dates
- 1 Jan 2018to 31 Dec 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: The study population comprises individuals with occupational claims related to exposure to hazardous substances recorded in the National Insurance Institute of Israel administrative database between January 1, 2018, and December 31, 2025. The nationwide dataset includes information on demographic characteristics, geographic distribution, exposure-related diagnoses, medical assessments, temporary and permanent disability determinations, assigned disability severity, and compensation classifications. Solar and sunlight-related conditions are excluded from the diagnostic analysis. The study includes all eligible administrative records without additional participant recruitment or clinical interventions.
Who may be able to join
- Individuals with occupational injury or disease claims related to exposure to hazardous chemical substances or other non-solar hazardous agents recorded in the National Insurance Institute of Israel database between January 1, 2018, and December 31, 2025.
- Claims classified as occupational substance exposure according to the administrative diagnostic and exposure classification system.
- Records containing information relevant to at least one study outcome, including demographic characteristics, clinical diagnoses, disability determinations, assigned disability percentages, or compensation classifications.
- Both male and female claimants.
- Workers 18 y.o. and higher
Who cannot join
- Claims exclusively related to solar radiation, sunlight exposure, or associated actinic conditions.
- Occupational claims unrelated to hazardous substance exposure.
- Records outside the study period.
- Records without sufficient information to establish eligibility for the occupational substance-exposure cohort.
- Duplicate administrative records representing the same determination, when identifiable. Separate legitimate claims or determinations relating to the same individual will not automatically be excluded.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Exposure to Hazardous Substances and Associated Disability: A Nationwide Eight-Year Study, 2018-2025
This clinical study aims to evaluate the effectiveness and safety of [intervention or treatment] in patients with [clinical condition]. The study will investigate whether this intervention improves [primary clinical outcome] compared with [standard treatment or control group]. Participants will undergo clinical assessment and follow-up according to the study protocol. The findings may provide additional evidence regarding the clinical effectiveness, safety, and potential benefits of this treatment.
Read the detailed description
This study is designed to investigate the clinical effectiveness and safety of [intervention] in patients diagnosed with [clinical condition]. The primary objective is to evaluate the effect of the intervention on [primary outcome]. Secondary objectives include the assessment of [secondary outcomes], treatment-related complications, and other relevant clinical parameters.
Eligible participants will be enrolled according to predefined inclusion and exclusion criteria. Participants will receive [description of intervention], and clinical outcomes will be assessed using standardized evaluation methods at predetermined follow-up intervals.
Data will be collected prospectively and analyzed to assess the primary and secondary study outcomes. Safety assessments will include the documentation of adverse events and treatment-related complications.
- Conditions
- Occupational Diseases
- Being tested
- Retrospective Administrative Data Assessment
- Keywords
- Hazardous substances, Contact Dermatitis, Toxic Effects of Chemical Substances, Disability burden
- Medical subject headings
- Occupational Diseases, Dermatitis, Contact
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Retrospective Administrative Data AssessmentOther
Retrospective analysis of existing occupational insurance records to evaluate hazardous substance-exposure claims, associated clinical conditions, and disability outcomes. No treatment, experimental exposure, or clinical intervention is administered.
| Study group | Role | What they receive |
|---|---|---|
| Workers With Occupational Exposure to Hazardous Substances | Workers with occupational claims related to exposure to hazardous chemical substances and other non-solar hazardous agents recorded in the National Insurance Institute of Israel database between January 2018 and December 2025. The study includes administrative information on demographic characteristics, occupational exposure-related diagnoses, geographic distribution, medical assessments, temporary and permanent disability determinations, assigned disability severity, and compensation classifications. Solar and sunlight-related conditions are excluded from the diagnostic analysis. All data were collected retrospectively from existing administrative records. Receives: Other: Retrospective Administrative Data Assessment |
What is being measured
The primary outcome is the main question the study is designed to answer.
Occupational Hazardous Substance-Exposure Claim Rate
Annual number of recognized occupational hazardous substance-exposure claims per 100,000 employed persons in Israel. Rates will be calculated using annual claim counts and the average national employed population. Temporal trends will be evaluated across the study period using regression models with appropriate denominator offsets. The outcome is an administrative claim rate rather than the incidence of occupational disease or exposure.
Measured: January 1, 2018, through December 31, 2025
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Oct 2026
- Study start1 Jan 2018
- Primary completion31 Dec 2025
- Study completion31 Dec 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (3)Papers the sponsor has linked to this study.
- Other trials for Occupational DiseasesStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 1,951 participants (actual)
Sponsor and investigators
- Lead sponsor
- Sergio Gabriel Susmallian
- Sponsor type
- University, hospital or other
- Collaborators
- Assuta Medical Center
- Responsible party
- Sponsor-investigator, Sergio Gabriel Susmallian, Assuta Medical Center
- Investigators
- Yoram Chaiter, Study director, National Insurance Institute of Israel
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07879261
- Sponsor's protocol ID
- BTL 005-2026
- Acronym
- Substances
- Status last verified
- Oct 2026
- First submitted
- 10 Oct 2026
- Last updated
- 16 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Individual participant data will not be publicly shared because the study uses confidential administrative records obtained from the National Insurance Institute of Israel. Access to individual-level data is restricted by applicable privacy regulations, institutional policies, and data-use agreements. De-identified aggregate results, statistical summaries, and methodological information may be made available in scientific publications or upon reasonable request, subject to institutional approval.
Publications
Jacobsen G, Rasmussen K, Bregnhoj A, Isaksson M, Diepgen TL, Carstensen O. Causes of irritant contact dermatitis after occupational skin exposure: a systematic review. Int Arch Occup Environ Health. 2022 Jan;95(1):35-65. doi: 10.1007/s00420-021-01781-0. Epub 2021 Oct 19.
PubMed 34665298Schutte MG, Tamminga SJ, de Groene GJ, Kezic S, van der Molen HF. Work-related and personal risk factors for occupational contact dermatitis: A systematic review of the literature with meta-analysis. Contact Dermatitis. 2023 Mar;88(3):171-187. doi: 10.1111/cod.14253. Epub 2022 Dec 12.
PubMed 36444496Feveile H, Christensen KB, Flyvholm MA. Self-reported occupational skin contact with cleaning agents and the risk of disability pension. Contact Dermatitis. 2009 Mar;60(3):131-5. doi: 10.1111/j.1600-0536.2008.01495.x.
PubMed 19260909
Study at a glance
From the registry record, last updated by the sponsor on 16 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Exposure to Hazardous Substances and Associated Disability: A Nationwide Eight-Year Study, 2018-2025
- ClinicalTrials.gov ID
- NCT07879261
- Acronym / sponsor ID
- Substances / BTL 005-2026
- Conditions
- Occupational Diseases
- Keywords
- Hazardous substances, Contact Dermatitis, Toxic Effects of Chemical Substances, Disability burden
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 1,951 participants (actual)
- Lead sponsor
- Sergio Gabriel SusmallianUniversity, hospital or other
- Collaborators
- Assuta Medical Center
- Study start
- 1 Jan 2018 (actual)
- Primary completion
- 31 Dec 2025 (actual)
- Study completion
- 31 Dec 2025 (actual)
- First posted
- 16 Oct 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This clinical study aims to evaluate the effectiveness and safety of [intervention or treatment] in patients with [clinical condition]. The study will investigate whether this intervention improves [primary clinical outcome] compared with [standard treatment or control group]. Participants will undergo clinical assessment and follow-up according to the study protocol. The findings may provide additional evidence regarding the clinical effectiveness, safety, and potential benefits of this treatment.
Detailed description
This study is designed to investigate the clinical effectiveness and safety of [intervention] in patients diagnosed with [clinical condition]. The primary objective is to evaluate the effect of the intervention on [primary outcome]. Secondary objectives include the assessment of [secondary outcomes], treatment-related complications, and other relevant clinical parameters.
Eligible participants will be enrolled according to predefined inclusion and exclusion criteria. Participants will receive [description of intervention], and clinical outcomes will be assessed using standardized evaluation methods at predetermined follow-up intervals.
Data will be collected prospectively and analyzed to assess the primary and secondary study outcomes. Safety assessments will include the documentation of adverse events and treatment-related complications.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Workers With Occupational Exposure to Hazardous Substances | – | Other: Retrospective Administrative Data AssessmentWorkers with occupational claims related to exposure to hazardous chemical substances and other non-solar hazardous agents recorded in the National Insurance Institute of Israel database between January 2018 and December 2025. The study includes administrative information on demographic characteristics, occupational exposure-related diagnoses, geographic distribution, medical assessments, temporary and permanent disability determinations, assigned disability severity, and compensation classifications. Solar and sunlight-related conditions are excluded from the diagnostic analysis. All data were collected retrospectively from existing administrative records. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- The study population comprises individuals with occupational claims related to exposure to hazardous substances recorded in the National Insurance Institute of Israel administrative database between January 1, 2018, and December 31, 2025. The nationwide dataset includes information on demographic characteristics, geographic distribution, exposure-related diagnoses, medical assessments, temporary and permanent disability determinations, assigned disability severity, and compensation classifications. Solar and sunlight-related conditions are excluded from the diagnostic analysis. The study includes all eligible administrative records without additional participant recruitment or clinical interventions.
Key inclusion criteria (5 listed)
- Individuals with occupational injury or disease claims related to exposure to hazardous chemical substances or other non-solar hazardous agents recorded in the National Insurance Institute of Israel database between January 1, 2018, and December 31, 2025.
- Claims classified as occupational substance exposure according to the administrative diagnostic and exposure classification system.
- Records containing information relevant to at least one study outcome, including demographic characteristics, clinical diagnoses, disability determinations, assigned disability percentages, or compensation classifications.
- Both male and female claimants.
- Workers 18 y.o. and higher
Key exclusion criteria (5 listed)
- Claims exclusively related to solar radiation, sunlight exposure, or associated actinic conditions.
- Occupational claims unrelated to hazardous substance exposure.
- Records outside the study period.
- Records without sufficient information to establish eligibility for the occupational substance-exposure cohort.
- Duplicate administrative records representing the same determination, when identifiable. Separate legitimate claims or determinations relating to the same individual will not automatically be excluded.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Retrospective Administrative Data AssessmentRetrospective analysis of existing occupational insurance records to evaluate hazardous substance-exposure claims, associated clinical conditions, and disability outcomes. No treatment, experimental exposure, or clinical intervention is administered. | Other | Workers With Occupational Exposure to Hazardous Substances |
Primary outcome
Occupational Hazardous Substance-Exposure Claim Rate
Time frame: January 1, 2018, through December 31, 2025
Annual number of recognized occupational hazardous substance-exposure claims per 100,000 employed persons in Israel. Rates will be calculated using annual claim counts and the average national employed population. Temporal trends will be evaluated across the study period using regression models with appropriate denominator offsets. The outcome is an administrative claim rate rather than the incidence of occupational disease or exposure.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Oct 2026.
- Background: PubMed 34665298Jacobsen G, Rasmussen K, Bregnhoj A, Isaksson M, Diepgen TL, Carstensen O. Causes of irritant contact dermatitis after occupational skin exposure: a systematic review. Int Arch Occup Environ Health. 2022 Jan;95(1):35-65. doi: 10.1007/s00420-021-01781-0. Epub 2021 Oct 19.
- Background: PubMed 36444496Schutte MG, Tamminga SJ, de Groene GJ, Kezic S, van der Molen HF. Work-related and personal risk factors for occupational contact dermatitis: A systematic review of the literature with meta-analysis. Contact Dermatitis. 2023 Mar;88(3):171-187. doi: 10.1111/cod.14253. Epub 2022 Dec 12.
- Background: PubMed 19260909Feveile H, Christensen KB, Flyvholm MA. Self-reported occupational skin contact with cleaning agents and the risk of disability pension. Contact Dermatitis. 2009 Mar;60(3):131-5. doi: 10.1111/j.1600-0536.2008.01495.x.
- Individual participant dataSharing planned: No. Individual participant data will not be publicly shared because the study uses confidential administrative records obtained from the National Insurance Institute of Israel. Access to individual-level data is restricted by applicable privacy regulations, institutional policies, and data-use agreements. De-identified aggregate results, statistical summaries, and methodological information may be made available in scientific publications or upon reasonable request, subject to institutional approval.
Related trials for Occupational Diseases
Enrolling by invitation
PATH to Reducing Burnout Among Peers Who Deliver Overdose Prevention Services (R33 Phase Clinical Trial)
Burnout, Secondary Trauma
Not yet recruitingObservational study
Circadian Clock Proteins in Gingival Crevicular Fluid of Individuals With and Without Circadian Rhythm Disruption
Gingivitis, Circadian Rhythm Disruption
RecruitingPhase 4
Lemborexant in Delayed Sleep Phase Syndrome
Delayed Sleep Phase Syndrome
Enrolling by invitationObservational study
Collection and Distribution of Samples From Healthy Donors for In Vitro Research at the NCI-Frederick
Healthy Donors
Recruiting
Development & Validation of a Life Balance Program for Parents of Preschoolers: A Pilot Study
Parenting Stress, Mental Health
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Yoram Chaiter study director
National Insurance Institute of Israel
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Occupational Diseases, run by Sergio Gabriel Susmallian at 1 site in Israel.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 16 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Israel. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Occupational Hazardous Substance-Exposure Claim Rate (time frame: January 1, 2018, through December 31, 2025). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07879261, which also lists 3 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Oct 2026.